NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
3.09
Dollar change
-0.04
Percentage change
-1.28
%
IndexRUT P/E- EPS (ttm)-0.40 Insider Own22.38% Shs Outstand191.48M Perf Week-9.38%
Market Cap591.82M Forward P/E- EPS next Y-0.20 Insider Trans-0.18% Shs Float148.66M Perf Month-10.17%
Enterprise Value484.71M PEG- EPS next Q-0.04 Inst Own58.84% Short Float8.64% Perf Quarter-11.71%
Income-76.57M P/S92.47 EPS this Y34.74% Inst Trans9.23% Short Ratio13.37 Perf Half Y-2.83%
Sales6.40M P/B7.47 EPS next Y17.34% ROA-57.29% Short Interest12.84M Perf YTD-5.50%
Book/sh0.41 P/C5.25 EPS next 5Y49.14% ROE-79.02% 52W High4.72 -34.60% Perf Year2.66%
Cash/sh0.59 P/FCF- EPS past 3/5Y23.21% 33.46% ROIC-90.95% 52W Low2.70 14.23% Perf 3Y5.82%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-17.50% 0.53% Gross Margin78.84% Volatility4.03% 3.72% Perf 5Y50.73%
Dividend TTM- EV/Sales75.74 EPS Y/Y TTM8.01% Oper. Margin-996.69% ATR (14)0.14 Perf 10Y-76.54%
Dividend Ex-Date- Quick Ratio6.01 Sales Y/Y TTM-50.69% Profit Margin-1195.86% RSI (14)32.83 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio6.01 EPS Q/Q-26.33% SMA20-9.44% Beta1.21 Target Price5.25
Payout- Debt/Eq0.07 Sales Q/Q15.14% SMA50-7.66% Rel Volume1.17 Prev Close3.13
Employees44 LT Debt/Eq0.06 EarningsMay 14 BMO SMA200-11.58% Avg Volume960.25K Price3.09
IPOJul 23, 2007 Option/ShortYes / Yes EPS/Sales Surpr.-25.00% 10.61% Trades Volume1,126,036 Change-1.28%
Date Action Analyst Rating Change Price Target Change
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Jun-25-25 07:30AM
May-14-25 08:45AM
07:39AM
07:30AM
May-13-25 05:15PM
09:40AM Loading…
09:40AM
May-07-25 02:01AM
Apr-25-25 09:40AM
Apr-24-25 10:02AM
Apr-23-25 02:01AM
Mar-31-25 12:00PM
09:40AM
Mar-28-25 09:48AM
09:00AM
07:01AM
08:45AM Loading…
Mar-27-25 08:45AM
07:30AM
Mar-26-25 03:45PM
Mar-03-25 09:15AM
Feb-25-25 07:00AM
Feb-12-25 09:24AM
Jan-16-25 11:22AM
Jan-13-25 07:30AM
Dec-06-24 08:20AM
Dec-03-24 08:00AM
Nov-26-24 07:30AM
Nov-15-24 11:02AM
11:01AM
Nov-14-24 07:30AM
Nov-07-24 02:12AM
02:07AM Loading…
02:07AM
Nov-06-24 08:45AM
07:40AM
07:30AM
Oct-23-24 07:30AM
Oct-15-24 08:16AM
Oct-01-24 07:30AM
Sep-25-24 09:40AM
Sep-03-24 07:30AM
Aug-22-24 09:40AM
Aug-06-24 09:40AM
Aug-02-24 01:51AM
Aug-01-24 08:40AM
07:41AM
07:30AM
Jul-18-24 07:30AM
Jun-06-24 11:15AM
11:15AM
Jun-05-24 02:30AM
May-29-24 07:30AM
May-22-24 02:00AM
May-17-24 12:03PM
10:40AM
09:00AM
May-07-24 07:30AM
May-03-24 11:19AM
03:24AM
May-02-24 12:55PM
08:58AM
08:45AM
07:44AM
07:30AM
07:25AM
Apr-30-24 09:40AM
Apr-18-24 07:30AM
Apr-04-24 08:30AM
Mar-08-24 07:30AM
Mar-01-24 08:17AM
Feb-29-24 11:14PM
08:40AM
07:52AM
07:30AM
Feb-15-24 07:30AM
Jan-08-24 07:30AM
Nov-09-23 04:24PM
04:01PM
09:12AM
Nov-08-23 07:30AM
01:16AM
Nov-07-23 08:05AM
07:40AM
07:30AM
07:15AM
Oct-30-23 09:32AM
Oct-24-23 07:30AM
Oct-18-23 07:30AM
Oct-11-23 08:05AM
Sep-12-23 10:56AM
08:58AM
Sep-11-23 04:15PM
Sep-07-23 07:30AM
Aug-04-23 03:29PM
Aug-03-23 08:55AM
07:49AM
07:30AM
Jul-23-23 10:19AM
Jul-20-23 07:30AM
Jul-12-23 07:30AM
Jul-10-23 04:01PM
Jun-23-23 09:40AM
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McElhaugh Michael J.DirectorApr 21 '25Proposed Sale3.26246,886804,850Apr 21 02:11 PM
McElhaugh Michael J.DirectorApr 15 '25Proposed Sale3.2053,114170,098Apr 15 04:27 PM
Sofia Michael J.OfficerMar 31 '25Proposed Sale3.50250,000875,000Mar 31 09:42 AM
Sofia Michael J.OfficerMar 24 '25Proposed Sale3.28250,000820,000Mar 24 09:19 AM
Sofia Michael J.OfficerMar 19 '25Proposed Sale3.20150,000480,000Mar 19 09:34 AM
Sofia Michael J.OfficerMar 13 '25Proposed Sale3.38100,000338,000Mar 13 03:55 PM
Sofia Michael J.Member of immediate family of Mar 07 '25Proposed Sale3.29167,162549,963Mar 07 02:59 PM
HASTINGS DAVID CChief Financial OfficerFeb 04 '25Sale3.2822,18372,827159,724Feb 05 04:02 PM
Sims KarenChief Medical OfficerFeb 04 '25Sale3.2819,34863,519106,194Feb 05 04:02 PM
McElhaugh Michael J.Interim President & CEOFeb 04 '25Sale3.2823,79078,1031,481,003Feb 05 04:02 PM
Naftzger J. ChristopherGeneral Counsel and CCOFeb 04 '25Sale3.2811,33337,20686,244Feb 05 04:02 PM
David C. HastingsOfficerFeb 04 '25Proposed Sale3.2822,18372,827Feb 04 08:39 PM
Karen SimsOfficerFeb 04 '25Proposed Sale3.2819,34863,519Feb 04 08:38 PM
Michael J. McElhaughDirector and OfficerFeb 04 '25Proposed Sale3.2823,79078,103Feb 04 08:36 PM
J. Christopher NaftzgerOfficerFeb 04 '25Proposed Sale3.2811,33337,206Feb 04 08:34 PM
MANCHESTER KEITH SDirectorAug 14 '24Option Exercise0.5654,91530,75254,915Aug 16 04:07 PM
MANCHESTER KEITH SDirectorAug 14 '24Sale3.698,84632,63746,069Aug 16 04:07 PM